|
Comparison between application for six minute walk test and conventional six minute walk test in people with coronary heart disease, chronic kidney disease, chronic obstructive pulmonary disease and stroke |
|---|---|
| รหัสดีโอไอ | |
| Title | Comparison between application for six minute walk test and conventional six minute walk test in people with coronary heart disease, chronic kidney disease, chronic obstructive pulmonary disease and stroke |
| Creator | Kulpriya Wechkama Spivey |
| Contributor | Kornanong Yuenyongchaiwat, Advisor |
| Publisher | Thammasat University |
| Publication Year | 2567 |
| Keyword | Six-minute walk test, Mobile application, Coronary heart disease, Chronic kidney disease, Chronic obstruction pulmonary, Stroke |
| Abstract | 6-minute walk test (6MWT) is a widely use sub-maximal test for asseesing functional capacity. Nowadays, medical technology plays a significant role for evaluation of health status. There was a the developed device for 6MWT has been experimentally used in healthy populations, their application in clinical populations remains limited. Patients with coronary artery disease (CAD), chronic kidney disease (CKD), chronic obstructive pulmonary disease (COPD), and stroke typically exhibit reduced functional capacity and frequently undergo 6MWT for functional assessment. Therefore, the aim of this study was to investigate the accuracy between mobile application and standard device used for testing patients in these 4 groups. Methods: One-hundred males and females, aged 40-80 years, diagnosed with CAD, CKD, COPD, or stroke, were enrolled in the study. Participants were asked to wear a mobile application device on the wrist of their dominant hand, or on the non-affected hand in the case of stroke patients, while performing the standard 6MWT protocol. Upon completion of the walk, the total walking distances were recorded and compared between the mobile application and the conventional 6MWT. Results: There were no statistically significant difference in between 6MWD from mobile application and conventional 6MWD in CAD (Mean difference = 12.60 ± 9.28 meters, 4.09 ± 2.92 %, p = 0.187), CKD (Mean difference = 8.39 ± 8.46 meters, 2.81 ± 13.34 %, p = 0.331) and COPD group (Mean difference = 2.07 ± 7.98 meters, 0.62 ± 1.06 %, p = 0.798). In contrast, there were statistically significant difference between total 6MWD from mobile application and conventional 6MWD (mean difference = 15.29 ± 4.95 meter, 5.29 ± 10.84 %, p = 0.003) and in stroke group (mean difference = 38.10 ± 12.30 meters, 17.63 ±11.85 %, p = 0.005). Moreover, to determine the generalizability of the medical device, the Maximum Permissible Error (MPE), set at 5%, was considered. Based on this criterion, the mobile application could be considered applicable for use in populations with CAD, CKD, and COPD, as the observed error falls within the acceptable range. Conclusion: The innovative wearable sensor prototype with a mobile application, demonstrates potential as an effective tool for evaluating physical performance in patients with CAD, CKD, and COPD. However, discrepancies were observed in the stroke group, suggesting the need for further validation and refinement of the technology in clinical settings. |
